Showing 2231-2240 of 4162 results for "".
- Candela Launches Vbeam Primahttps://modernaesthetics.com/news/canola-launches-vbeam-prima/2472064/Recently FDA-cleared, the Vbeam Prima from Candela offers two wavelengths to effectively treat a broad range of skin conditions including rosacea, spider veins, wrinkles, acne and more. Vbeam Prima’s re-designed 595 nm PD
- First-ever Data on Vaginal Regeneration for ThermiVahttps://modernaesthetics.com/news/first-ever-data-on-vaginal-regeneration-for-thermiva/2472081/Thermi’s ThermiVa® device has been shown to deliver significant improvements in common vaginal disorders and improve sexual satisfaction, according to a study published in Dermatologic Surgery. Since it was cleared by the FDA in 2013, ThermiVa has been used in more t
- Jacob Chacko, MD Joins Bonti's Board of Directorshttps://modernaesthetics.com/news/jacob-chackomd-joins-bontis-board-of-directors/2472135/Jacob Chacko, MD has joined Bonti’s Board of Directors. Dr. Chacko has served as the Chief Financial Officer of Ignyta, Inc. since May 2014. At Ignyta, he leads multiple functions, including Finance, Accounting, Investor Relations, Comm
- Juvéderm Vollure XC FDA Approved for Correction of Facial Wrinkles and Foldshttps://modernaesthetics.com/news/juvderm-vollure-xc-fda-approved-for-correction-of-facial-wrinkles-and-folds/2472255/The FDA has approved Allergan plc's Juvéderm Vollure XC for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21. In the US pivotal clinical trial, a majority (59 percent) of subjects saw improvement in moderate to severe na
- Systematic Review Examines Vaginal Laser and Radiofrequency for Stress Urinary Incontinencehttps://modernaesthetics.com/news/systematic-review-examines-vaginal-laser-and-radiofrequency-for-stress-urinary-incontinence/2486518/In a systematic review and meta-analysis published in International Urogynecology Journal, investigators reported that energy-based devices may offer modest short-term symptom improvement for women with stress urinary incontinence compared with sham treatment. David Lukanović, Gee
- GPX4 Modulator Shows Early Promise in First-in-Human Studyhttps://modernaesthetics.com/news/gpx4-modulator-shows-early-promise-in-first-in-human-study/2486474/A novel topical therapy targeting cellular senescence showed early biologic activity across multiple dermatologic conditions in a Phase 1 clinical trial, according to data presented by Frederick Beddingfield III, MD, PhD, FAAD, at the Dermatology Innovation Forum during the American Academy of De
- AAD 2026: New Study Highlights Dual-Action Antioxidant Serum for UV-Induced Skin Protectionhttps://modernaesthetics.com/news/aad-2026-new-study-highlights-dual-action-antioxidant-serum-for-uv-induced-skin-protection/2486463/New research presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting highlights the potential of a multifunctional antioxidant serum, AOX2.0, to protect human skin from ultraviolet (UV)-induced damage while supporting epidermal recovery. The study examined how oxidative stress
- SkinPen Milestone Highlights Growth in Microneedling Demandhttps://modernaesthetics.com/news/skinpen-milestone-highlights-growth-in-microneedling-demand/2486459/Revance announced that it has distributed more than 1 million SkinPen treatment kits nationwide since January 2025, marking a milestone for the company’s microneedling portfolio. The achievement comes approximately 1 year after the launch of SkinPen Precision Elite, the latest iteration of the de
- Molecular Profiling Reveals Personalized Pathways in Skin Aginghttps://modernaesthetics.com/news/molecular-profiling-reveals-personalized-pathways-in-skin-aging/2486451/A translational biomarker study presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlighted distinct molecular signatu
- AAD 2026: RelabotulinumtoxinA Shows Consistent Efficacy Across Age Groupshttps://modernaesthetics.com/news/aad-2026-relabotulinumtoxina-shows-consistent-efficacy-across-age-groups/2486431/A post hoc analysis presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, evaluated the impact of age on outcomes with relabotulinumtoxinA in patients with moderate-to-severe glabellar lines (GLs) and lateral canthal lines (LCLs). The analysis pooled data